Skip to main content

Digital Trends may earn a commission when you buy through links on our site. Why trust us?

Gene therapy helps people with monochrome vision to see in color

Promotional image for Tech For Change. Person standing on solar panel looking at sunset.
This story is part of Tech for Change: an ongoing series in which we shine a spotlight on positive uses of technology, and showcase how they're helping to make the world a better place.
 

Color blindness is usually a hereditary condition. While there have been a few high-tech methods, such as special glasses, to help people deal with it, to date there hasn’t been much in the way of a permanent solution to the problem. Perhaps until now, that is.

Recommended Videos

An initial trial in patients suggests that a new gene therapy treatment for helping overcome color blindness, developed by researchers in Germany, is completely safe. The researchers also obtained evidence that the treatment works.

The condition in question, referred to as achromatopsia, is one of the rarer types of color blindness. Approximately 8% of men and 0.5% of women have some kind of color blindness which renders them unable to see certain colors (red-green color blindness being the most common). Achromatopsia, however, affects just 1 out of 33,000 people — which nonetheless adds up to a sizable cohort of people worldwide. The condition is due to non-functioning or absent retinal cones, and it makes the world appear entirely black and white. It also causes blurred vision and makes eyes extremely sensitive to bright light.

In around one-third of patients with achromatopsia, the condition is caused by a gene called CNGA3. The new treatment, developed by researchers at the Institute for Ophthalmic Research at the University Hospitals in Tübingen and Departments of Pharmacy and Ophthalmology at Ludwig Maximilian University of Munich, makes it possible to inject a corrected version of the gene into a patient’s retina using a harmless virus.

A trial involving nine achromatopsia patients, aged between 24 and 59, was recently carried out at the University Eye Hospital Tübingen. There were no health issues, and the retina suffered no permanent change or damage as a result of the procedure. Patients involved in the study saw their vision improve in terms of focus, contrast perception, and — most crucially — color vision.

“The study is an important first step,” Martin Biel from the Department of Pharmacy at LMU, said in a statement. “It represents a milestone on the road to a curative therapy of achromatopsia, and we expect even better treatment success in the future.”

A paper describing the research was recently published in the journal JAMA Ophthalmology 2020.

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Google just gave vision to AI, but it’s still not available for everyone
Gemini Live App on the Galaxy S25 Ultra broadcast to a TV showing the Gemini app with the camera feature open

Google has just officially announced the roll out of a powerful Gemini AI feature that means the intelligence can now see.

This started in March as Google began to show off Gemini Live, but it's now become more widely available.

Read more
This modular Pebble and Apple Watch underdog just smashed funding goals
UNA Watch

Both the Pebble Watch and Apple Watch are due some fierce competition as a new modular brand, UNA, is gaining some serous backing and excitement.

The UNA Watch is the creation of a Scottish company that wants to give everyone modular control of smartwatch upgrades and repairs.

Read more
Tesla, Warner Bros. dodge some claims in ‘Blade Runner 2049’ lawsuit, copyright battle continues
Tesla Cybercab at night

Tesla and Warner Bros. scored a partial legal victory as a federal judge dismissed several claims in a lawsuit filed by Alcon Entertainment, a production company behind the 2017 sci-fi movie Blade Runner 2049, Reuters reports.
The lawsuit accused the two companies of using imagery from the film to promote Tesla’s autonomous Cybercab vehicle at an event hosted by Tesla CEO Elon Musk at Warner Bros. Discovery (WBD) Studios in Hollywood in October of last year.
U.S. District Judge George Wu indicated he was inclined to dismiss Alcon’s allegations that Tesla and Warner Bros. violated trademark law, according to Reuters. Specifically, the judge said Musk only referenced the original Blade Runner movie at the event, and noted that Tesla and Alcon are not competitors.
"Tesla and Musk are looking to sell cars," Reuters quoted Wu as saying. "Plaintiff is plainly not in that line of business."
Wu also dismissed most of Alcon's claims against Warner Bros., the distributor of the Blade Runner franchise.
However, the judge allowed Alcon to continue its copyright infringement claims against Tesla for its alleged use of AI-generated images mimicking scenes from Blade Runner 2049 without permission.
Alcan says that just hours before the Cybercab event, it had turned down a request from Tesla and WBD to use “an icononic still image” from the movie.
In the lawsuit, Alcon explained its decision by saying that “any prudent brand considering any Tesla partnership has to take Musk’s massively amplified, highly politicized, capricious and arbitrary behavior, which sometimes veers into hate speech, into account.”
Alcon further said it did not want Blade Runner 2049 “to be affiliated with Musk, Tesla, or any Musk company, for all of these reasons.”
But according to Alcon, Tesla went ahead with feeding images from Blade Runner 2049 into an AI image generator to yield a still image that appeared on screen for 10 seconds during the Cybercab event. With the image featured in the background, Musk directly referenced Blade Runner.
Alcon also said that Musk’s reference to Blade Runner 2049 was not a coincidence as the movie features a “strikingly designed, artificially intelligent, fully autonomous car.”

Read more